ΔFOSB
is a uniquely stable member of the FOS family of immediate
early gene AP1 transcription factors. Its accumulation in specific
cell types and tissues in response to a range of chronic stimuli is
associated with biological phenomena as diverse as memory formation,
drug addiction, stress resilience, and immune cell activity. Causal
connections between ΔFOSB expression and the physiological and
behavioral sequelae of chronic stimuli have been established in rodent
and, in some cases, primate models for numerous healthy and pathological
states with such preclinical observations often supported by human
data demonstrating tissue-specific ΔFOSB expression associated
with several specific syndromes. However, the viability of ΔFOSB
as a target for therapeutic intervention might be questioned over
presumptive concerns of side effects given its expression in such
a wide range of cell types and circumstances. Here, we summarize numerous
insights from the past three decades of research into ΔFOSB
structure, function, mechanisms of induction, and regulation of target
genes that support its potential as a druggable target. We pay particular
attention to the potential for targeting distinct ΔFOSB isoforms
or distinct ΔFOSB-containing multiprotein complexes to achieve
cell type or tissue specificity to overcome off-target concerns. We
also cover critical gaps in knowledge that currently limit the exploitation
of ΔFOSB’s therapeutic possibilities and how they may
be addressed. Finally, we summarize both current and potential future
strategies for generating small molecules or genetic tools for the
manipulation of ΔFOSB in the clinic.